AU2013334081B2 - Methods for controlling blood pressure and reducing dyspnea in heart failure - Google Patents

Methods for controlling blood pressure and reducing dyspnea in heart failure Download PDF

Info

Publication number
AU2013334081B2
AU2013334081B2 AU2013334081A AU2013334081A AU2013334081B2 AU 2013334081 B2 AU2013334081 B2 AU 2013334081B2 AU 2013334081 A AU2013334081 A AU 2013334081A AU 2013334081 A AU2013334081 A AU 2013334081A AU 2013334081 B2 AU2013334081 B2 AU 2013334081B2
Authority
AU
Australia
Prior art keywords
blood pressure
clevidipine
patient
mmhg
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013334081A
Other languages
English (en)
Other versions
AU2013334081A1 (en
Inventor
Ming-yi HU
Loretta M. Itri
Edward C. Spindler Jr.
Gregory Charles Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chiesi Farmaceutici SpA
Original Assignee
Chiesi Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farmaceutici SpA filed Critical Chiesi Farmaceutici SpA
Publication of AU2013334081A1 publication Critical patent/AU2013334081A1/en
Assigned to CHIESI FARMACEUTICI S.P.A. reassignment CHIESI FARMACEUTICI S.P.A. Request for Assignment Assignors: THE MEDICINES COMPANY
Application granted granted Critical
Publication of AU2013334081B2 publication Critical patent/AU2013334081B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2013334081A 2012-10-26 2013-10-26 Methods for controlling blood pressure and reducing dyspnea in heart failure Active AU2013334081B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261719127P 2012-10-26 2012-10-26
US61/719,127 2012-10-26
PCT/US2013/066990 WO2014066870A1 (en) 2012-10-26 2013-10-26 Methods for controlling blood pressure and reducing dyspnea in heart failure

Publications (2)

Publication Number Publication Date
AU2013334081A1 AU2013334081A1 (en) 2015-06-11
AU2013334081B2 true AU2013334081B2 (en) 2017-05-18

Family

ID=50545374

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013334081A Active AU2013334081B2 (en) 2012-10-26 2013-10-26 Methods for controlling blood pressure and reducing dyspnea in heart failure

Country Status (18)

Country Link
US (1) US10881645B2 (enExample)
EP (1) EP2925128B1 (enExample)
JP (2) JP6329957B2 (enExample)
KR (1) KR102299073B1 (enExample)
CN (2) CN104968199A (enExample)
AU (1) AU2013334081B2 (enExample)
BR (1) BR112015009291B1 (enExample)
CA (1) CA2889584C (enExample)
EA (1) EA030354B1 (enExample)
ES (1) ES2671639T3 (enExample)
IL (1) IL238462A0 (enExample)
MX (1) MX359768B (enExample)
NZ (1) NZ708511A (enExample)
PL (1) PL2925128T3 (enExample)
TR (1) TR201807636T4 (enExample)
UA (1) UA117571C2 (enExample)
WO (1) WO2014066870A1 (enExample)
ZA (1) ZA201503741B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102380701B1 (ko) * 2014-05-19 2022-03-31 치에시 파마슈티시 에스.피.아. 클레비디핀 나노입자 및 그의 제약적 조성물
EP3934654A1 (en) * 2019-03-05 2022-01-12 Windtree Therapeutics, Inc. Istaroxime-containing intravenous formulation for the treatment of acute heart failure (ahf)
CN114966056B (zh) * 2022-06-08 2024-07-02 四川大学华西医院 筛查急性主动脉夹层的试剂盒和系统

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012135617A1 (en) * 2011-04-01 2012-10-04 The Medicines Company Short -acting dihydropyridines (clevidipine) for use in reducing stroke damage

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9303657D0 (sv) 1993-11-05 1993-11-05 Astra Ab Short-acting dihydropyridines
SE9303744D0 (sv) 1993-11-12 1993-11-12 Astra Ab Pharmaceutical emulsion
SE9804002D0 (sv) 1998-11-23 1998-11-23 Astra Ab New manufacturing process
CA2724540C (en) 2008-05-16 2014-07-08 Corthera, Inc. Treating dyspnea associated with acute heart failure with relaxin
KR101772602B1 (ko) 2008-08-01 2017-08-29 치에시 파마슈티시 에스.피.아. 약제학적 조성물 및 그의 저 불순물 농축물을 제조하는 방법
WO2010014234A1 (en) 2008-08-01 2010-02-04 The Medicines Company Pharmaceutical compositions and methods for stabilizing the same
BR112012011298B1 (pt) 2009-11-11 2021-12-14 Chiesi Farmaceutici S.P.A. Uso de cangrelor e/ou bivalirudina na preparação de medicamentos e combinação de medicamentos
TW201215392A (en) 2010-06-16 2012-04-16 Gilead Sciences Inc Use of ranolazine for treating pulmonary hypertension
JP6040437B2 (ja) * 2010-10-12 2016-12-07 チエシイ ファルマセウティシ ソシエタ ペル アチオニＣｈｉｅｓｉ Ｆａｒｍａｃｅｕｔｉｃｉ Ｓ．Ｐ．Ａ． 抗菌剤を含むクレビジピン乳化製剤

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012135617A1 (en) * 2011-04-01 2012-10-04 The Medicines Company Short -acting dihydropyridines (clevidipine) for use in reducing stroke damage

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ERICKSON, A. L. et al. "Clevidipine: A short-acting intravenous dihydropyridine calcium channel blocker for the management of hypertension" Pharmacotherapy (2010) vol. 30, no. 5, pages 515-528 *

Also Published As

Publication number Publication date
MX2015005341A (es) 2016-05-24
EP2925128B1 (en) 2018-04-11
EP2925128A1 (en) 2015-10-07
CN104968199A (zh) 2015-10-07
CN110840890A (zh) 2020-02-28
BR112015009291A2 (pt) 2017-07-04
ZA201503741B (en) 2022-09-28
TR201807636T4 (tr) 2018-06-21
AU2013334081A1 (en) 2015-06-11
NZ708511A (en) 2018-11-30
US20140121247A1 (en) 2014-05-01
KR20150104084A (ko) 2015-09-14
ES2671639T3 (es) 2018-06-07
CA2889584C (en) 2018-08-14
CA2889584A1 (en) 2014-05-01
JP2015535258A (ja) 2015-12-10
EP2925128A4 (en) 2016-06-08
US10881645B2 (en) 2021-01-05
KR102299073B1 (ko) 2021-09-09
EA201590825A1 (ru) 2015-09-30
BR112015009291B1 (pt) 2021-03-16
WO2014066870A1 (en) 2014-05-01
JP2018065875A (ja) 2018-04-26
EA030354B1 (ru) 2018-07-31
UA117571C2 (uk) 2018-08-27
IL238462A0 (en) 2015-06-30
MX359768B (es) 2018-10-10
JP6329957B2 (ja) 2018-05-23
PL2925128T3 (pl) 2018-10-31

Similar Documents

Publication Publication Date Title
EP2986308B1 (en) Angiotensin ii in combination for the treatment of hypotension
AU2013334081B2 (en) Methods for controlling blood pressure and reducing dyspnea in heart failure
Ferguson-Myrthil Novel agents for the treatment of hyponatremia: a review of conivaptan and tolvaptan
EP3074045B1 (en) Sprayable aqueous composition comprising glyceryl trinitrate
RU2623039C2 (ru) Дигидропиридины (клевидипин) кратковременного действия для применения в восстановлении после инсульта
KR20200062240A (ko) 시포니모드의 투여 요법
JP6629850B2 (ja) 汎用心停止液（変種）
CN114222566A (zh) 用于改善癌症患者的结果的方法和组合物
US11911384B2 (en) Vasodilators for treatment of heart failure
CZ300888B6 (cs) Lécivo pro lécení srdecního selhání obsahující antagonistu kortizolu
KR20250005343A (ko) 심인성 쇼크 전 단계 및 심인성 쇼크의 치료를 위한 이스타록심-함유 정맥내 제제
HK40020897A (en) Methods for controlling blood pressure and reducing dyspnea in heart failure
KR20210032437A (ko) 심부전의 치료를 위한 신규한 약제학적 용도
Oommen et al. Droxidopa for hypotension of different etiologies: two case reports
WO2025128432A1 (en) Istaroxime and metabolite derivatives thereof for reducing the risk of acute myocardial arrhythmia
KR20250010046A (ko) IL-6 및/또는 IL-1β 억제제
Khatib Diuretics in heart failure part 2: considerations in practice
Brampton PrRAN™-LISINOPRIL
Kumar et al. Pharmacological strategies for the treatment of congestive heart failure
Fishbein Acute Decompensated Heart Failure: Treatment–Specific Therapies
Marti et al. Digoxin, Diuretics, and Vasodilators in Patients with Heart Failure
US20070244101A1 (en) Novel compositions and methods of treatment of type ii diabetes and hypertension

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: CHIESI FARMACEUTICI S.P.A.

Free format text: FORMER APPLICANT(S): THE MEDICINES COMPANY

FGA Letters patent sealed or granted (standard patent)